CHI3L1 and stroke disorder: YKL-40 long-term prognosis was evaluated after 3 months and one to 5 years using the mRS in patients with ischemic stroke or transient ischemic attack, and an independent association between YKL-40 levels with stroke recurrence, and an unfavorable outcome in the mRS were reported (Li et al., 2022).